Skip to main content
. Author manuscript; available in PMC: 2013 Mar 1.
Published in final edited form as: Neuropharmacology. 2011 Feb 17;62(3):1527–1543. doi: 10.1016/j.neuropharm.2011.01.048

TABLE 2.

Effects of adenosinergic drugs on PPI and its disruption by psychostimulants: MSX-3 (((E)-phosphoric acid mono-[3-[8-[2-(3-methoxyphenyl)); the full names of the other drugs are provided in Table 1. ↓ / ↑: attenuates / potentiates basal PPI or the drug-induced PPI disruption; ↔ no effect.

• Adenosinergic drugs on Sensorimotor gating measured by prepulse inhibition (PPI)
Adenosinergic drugs Adenosinergic action Effect References
CPA A1R agonist Sills et al., 1999
Schwienbacher et al., 2002
CGS21680 A2AR agonist Hauber and Koch, 1997
Sills et al., 2001
Caffeine A2AR antagonist Bakshi et al., 1995
MSX-3 A1R/A2R antagonist #x2193; Nagel et al., 2003
Theophylline Koch and Hauber, 1998
↓ / ↑: impairs / enhances PPI; ↔ no effect
• Adenosinergic drugs against psychostimulant-induced ppi deficit
PPI-disrupting agents Adenosinergic action Adenosinergic drugs Effect against PPI disrpution References
Amphetamine A2AR agonist CGS 21680 Sills et al., 2001
Apomorphine A1R agonist CPA #x2193; Koch and Hauber, 1998
A2AR agonist CGS 21680 #x2193; Hauber and Koch, 1997
Sills et al., 2001
A1R/A2R antagonist Theophylline Koch and Hauber, 1998
MK-801 / PCP A2AR agonist CPA #x2193; Sills et al., 1999
A2AR agonist CGS 21680 Sills et al., 2001
Wardas et al., 2003